Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8(th) Medical Center of PLA General Hospital, Beijing 100091, China.
Huadong Research Institute for Medicine and Biotechniques, Nanjing 210002, Jiangsu Province, China.
Int Immunopharmacol. 2022 Jul;108:108870. doi: 10.1016/j.intimp.2022.108870. Epub 2022 May 17.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), and its variants have brought unprecedented impacts to the global public health system, politics, economy, and other fields. Although more than ten COVID-19 specific vaccines have been approved for emergency use, COVID-19 prevention and control still face many challenges. Bacille Calmette-Guérin (BCG) is the only authorized vaccine used to fight against tuberculosis (TB), it has been hypothesized that BCG may prevent and control COVID-19 based on BCG-induced nonspecific immune responses. Herein, we summarized: 1) The nonspecific protection effects of BCG, such as prophylactic protection effects of BCG on nonmycobacterial infections, immunotherapy effects of BCG vaccine, and enhancement effect of BCG vaccine on unrelated vaccines; 2) Recent evidence of BCG's efficacy against SARS-COV-2 infection from ecological studies, analytical analyses, clinical trials, and animal studies; 3) Three possible mechanisms of BCG vaccine and their effects on COVID-19 control including heterologous immunity, trained immunity, and anti-inflammatory effect. We hope that this review will encourage more scientists to investigate further BCG induced non-specific immune responses and explore their mechanisms, which could be a potential tool for addressing the COVID-19 pandemic and COVID-19-like "Black Swan" events to reduce the impacts of infectious disease outbreaks on public health, politics, and economy.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是导致 2019 年冠状病毒病(COVID-19)的病原体,及其变体给全球公共卫生系统、政治、经济和其他领域带来了前所未有的影响。尽管已经批准了十多种 COVID-19 特异性疫苗用于紧急使用,但 COVID-19 的防控仍然面临许多挑战。卡介苗(BCG)是唯一获准用于防治结核病(TB)的疫苗,基于 BCG 诱导的非特异性免疫反应,人们假设 BCG 可能具有预防和控制 COVID-19 的作用。在此,我们总结了:1)BCG 的非特异性保护作用,如 BCG 对非分枝杆菌感染的预防作用、BCG 疫苗的免疫治疗作用以及 BCG 疫苗对非相关疫苗的增强作用;2)从生态研究、分析性分析、临床试验和动物研究中获得的 BCG 对 SARS-COV-2 感染的近期疗效证据;3)BCG 疫苗的三种可能机制及其对 COVID-19 控制的影响,包括异源免疫、训练免疫和抗炎作用。我们希望这篇综述将鼓励更多的科学家进一步研究 BCG 诱导的非特异性免疫反应及其机制,这可能是应对 COVID-19 大流行和 COVID-19 类“黑天鹅”事件的潜在工具,以减少传染病爆发对公共卫生、政治和经济的影响。